Sugi Predict

Sugi Predict / Compounds / SCHEMBL2108121

SCHEMBL2108121

SCHEMBL2108121

CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ GNPAT O15228 1/20 0.60
▸ OPRK1 P41145 5/20 0.52
▸ OPRM1 P35372 3/20 0.52
▸ ERAP2 Q6P179 1/20 0.51
▸ LNPEP Q9UIQ6 1/20 0.51
▸ CPB2 Q96IY4 1/20 0.51
▸ GHSR Q92847 1/20 0.50
▸ ECE1 P42892 1/20 0.49
▸ MMP2 P08253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1711756 1.00 GNPAT (0.60) GNPATOPRK1OPRM1ERAP2LNPEP
SCHEMBL1711761 1.00 GNPAT (0.60) GNPATOPRK1OPRM1ERAP2LNPEP
SCHEMBL2108111 1.00 GNPAT (0.60) GNPATOPRK1OPRM1ERAP2LNPEP
SCHEMBL8170666 0.96 GNPAT (0.58) GNPATOPRK1OPRM1ERAP2LNPEP
SCHEMBL31181294 0.96 GNPAT (0.55) GNPATOPRK1OPRM1ERAP2LNPEP
SCHEMBL31181267 0.96 GNPAT (0.55) GNPATOPRK1OPRM1ERAP2LNPEP
SCHEMBL31181210 0.95 GNPAT (0.54) GNPATOPRK1OPRM1ERAP2LNPEP
SCHEMBL29496448 0.94 GNPAT (0.53) GNPATOPRK1OPRM1ECE1
SCHEMBL30385347 0.94 GNPAT (0.53) GNPATOPRK1OPRM1ECE1
SCHEMBL30198611 0.94 BACE1 (0.55) GNPATOPRK1OPRM1ERAP2LNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1560599-A1 PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS Syntarga B.V. (NL) 2005-08-10 — — EP claimed
WO-2004043493-A1 PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS SYNTARGA B.V. (NL) 2004-05-27 — — WO claimed
EP-1370298-A1 ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS Syntarga B.V. (NL) 2003-12-17 — — EP claimed
WO-2002083180-A1 ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS SYNTARGA B.V. (NL) 2002-10-24 — — WO claimed
US-11419944-B2 Non-linear self-immolative linkers and conjugates thereof BYONDIS B.V. (NL) 2022-08-23 — — US disclosed
US-11052155-B2 Conjugates of CC-1065 analogs and bifunctional linkers SYNTARGA BV (NL) 2021-07-06 — — US disclosed
US-20200297859-A1 NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF BYONDIS B.V. (NL) 2020-09-24 — — US disclosed
EP-3525826-B1 NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF BYONDIS BV (NL) 2020-07-22 — — EP disclosed
EP-3108886-B1 CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS SYNTARGA BV (NL) 2020-06-17 — — EP disclosed
EP-3525826-A1 NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF Synthon Biopharmaceuticals B.V. (NL) 2019-08-21 — — EP disclosed
EP-1909846-B1 TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES COMPRISING THE SAME AND PROCESSES FOR THEIR PREPARATION SYNTARGA BV (NL) 2018-12-26 — — EP disclosed
US-20180147289-A9 Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers SYNTARGA BV (NL) 2018-05-31 — — US disclosed
US-8680293-B2 Substituted CC-1065 analogs and their conjugates SYNTARGA B.V. (NL) 2014-03-25 — — US disclosed
EP-2173739-B1 SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES SYNTARGA BV (NL) 2013-07-31 — — EP disclosed
US-8158590-B2 Triazole-containing releasable linkers, conjugates thereof, and methods of preparation SYNTARGA B.V. (NL) 2012-04-17 — — US disclosed
US-20110065767-A1 Substituted CC-1065 Analogs and Their Conjugates SYNTARGA B.V. (NL) 2011-03-17 — — US disclosed
US-20090318668-A1 Water-Soluble CC-1065 Analogs and Their Conjugates Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) 2009-12-24 — — US disclosed
US-20080311136-A1 Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation BYONDIS B.V. (NL) 2008-12-18 — — US disclosed
EP-1370298-A1 ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS Syntarga B.V. (NL) 2003-12-17 — — EP disclosed
WO-2002083180-A1 ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS SYNTARGA B.V. (NL) 2002-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318668-A1 Water-Soluble CC-1065 Analogs and Their Conjugates PCNA, DCK, BAD GNPAT 1927/4885OPRK1 2629/4885OPRM1 3942/4885
US-20200297859-A1 NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF DLST, ADSL, LANCL1 GNPAT 1411/4885OPRK1 3821/4885OPRM1 4169/4885
US-20080311136-A1 Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation PAICS, CD44, TRIM33 GNPAT 2453/4885OPRK1 4335/4885OPRM1 4659/4885
US-11052155-B2 Conjugates of CC-1065 analogs and bifunctional linkers PCNA, DCLRE1A, CDC5L GNPAT 1698/4885OPRK1 2745/4885OPRM1 3850/4885
US-20110065767-A1 Substituted CC-1065 Analogs and Their Conjugates PCNA, TOP1, TOP2B GNPAT 1256/4885OPRK1 2947/4885OPRM1 4151/4885
US-11419944-B2 Non-linear self-immolative linkers and conjugates thereof DLST, ADSL, LANCL1 GNPAT 1411/4885OPRK1 3821/4885OPRM1 4169/4885
US-20180147289-A9 Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers PCNA, DCLRE1A, CDC5L GNPAT 1859/4885OPRK1 3228/4885OPRM1 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.